Biolight (BOLT) AI Stock Analysis

0 Followers

Biolight

(TASE:BOLT)

Select Model

Rating:41Neutral

Price Target:ILA 283.00▼(-1.05% Downside)

Action:reiterated

Date:08/21/26

The score is driven down primarily by weak financial performance (minimal/zero revenue, sustained losses, and persistent cash burn), reinforced by poor technical momentum with the price below key moving averages and negative MACD. Valuation metrics provide limited support because losses make the P/E uninformative and no dividend yield is available.

Positive Factors

Low leverageVery low leverage reduces refinancing and solvency pressure, preserving more flexibility than a highly indebted balance sheet. This can help Biolight direct available resources toward product development and commercialization while limiting interest-related demands on future cash flow.

Negative Factors

Minimal and volatile revenueRevenue has not demonstrated a dependable growth trajectory and reached zero in the latest reported year. Such limited and volatile sales make it difficult to absorb the existing cost base, validate commercial traction, or establish a reliable foundation for sustainable earnings.

Biolight (BOLT) vs. iShares MSCI Israel ETF (EIS)

Market Cap: ILS 25.88M
Dividend Yield: ―
Average Volume (3M): 10.38K
Price to Earnings (P/E): -2.1
Beta (1Y): 0.64
Revenue Growth: -100.00%
EPS Growth: -29.02%
Country: Israel
Employees: 4
Sector: General
Sector Strength: 55
Industry: Medical - Specialties

Biolight Business Overview & Revenue Model

Company Description

BioLight Life Sciences Ltd. is an ophthalmic firm dedicated to discovering, developing, and bringing to market innovative products and pipeline candidates designed to tackle various eye-related ailments. Its portfolio and development pipeline include...

Biolight Financial Statement Overview

Summary

Overall financials indicate a high-risk profile: revenue is extremely small and volatile (including zero revenue in 2025), while operating and net losses persist and cash burn remains heavy. The key offsetting positive is very low leverage, but equity has been eroding due to ongoing losses.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	219.00K	118.00K	63.00K	3,000
Gross Profit	-270.00K	-544.00K	219.00K	118.00K	63.00K	3,000
EBITDA	-14.65M	-14.66M	-7.75M	-10.08M	-8.03M	-1.36M
Net Income	-11.74M	-11.73M	-7.14M	-26.02M	-7.85M	382.00K
Balance Sheet
Total Assets	35.06M	42.41M	34.12M	33.45M	57.01M	64.17M
Cash, Cash Equivalents and Short-Term Investments	16.19M	23.65M	13.47M	8.64M	17.63M	33.71M
Total Debt	1.06M	772.00K	599.00K	91.00K	527.00K	443.00K
Total Liabilities	3.86M	2.24M	3.38M	3.15M	3.32M	2.75M
Stockholders Equity	28.09M	34.40M	26.88M	29.78M	53.17M	60.70M
Cash Flow
Free Cash Flow	-11.92M	-10.86M	-11.02M	-10.99M	-9.64M	-10.65M
Operating Cash Flow	-11.92M	-10.85M	-10.99M	-9.58M	-9.54M	-10.03M
Investing Cash Flow	-11.96M	-16.17M	7.55M	-1.95M	-10.55M	13.48M
Financing Cash Flow	21.36M	21.37M	7.98M	3.25M	-485.00K	915.00K

Biolight Technical Analysis

Technical Analysis SentimentNegative

Last Price286.00

Price Trends

50DMA289.31Negative

100DMA326.86Negative

200DMA320.01Negative

Market Momentum

MACD-0.37Positive

RSI47.27Neutral

STOCH79.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BOLT, the sentiment is Negative. The current price of 286.00 is below the 20-day moving average (MA) of 287.60, below the 50-day MA of 289.31, and below the 200-day MA of 320.01, indicating a bearish trend. The MACD of -0.37 indicates Positive momentum. The RSI at 47.27 is Neutral, neither overbought nor oversold. The STOCH value of 79.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BOLT.

Biolight Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IL:BOLT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IL:PPBT	46Neutral	ILS 32.42M	-0.01	―	―	―	-125.74%
IL:BLRX	41Neutral	ILS 29.87M	-1.01	―	―	-93.07%	62.25%
IL:BOLT	41Neutral	ILS 25.74M	-2.12	―	―	-100.00%	-29.02%
IL:CANF	38Underperform	ILS 16.46M	-0.24	―	―	―	―

* General Sector Average

Performance Comparison

IL:BOLT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IL:BOLT	BioLight Life Sciences Ltd.	286.00	-117.10	-29.05%
IL:BONS	Bonus Biogroup	15.80	-6.20	-28.18%
IL:CBI	Clal Biotechnology Industries Ltd	23.30	-7.90	-25.32%
IL:BLRX	BioLineRX Ltd.	1.00	-0.90	-47.37%
IL:CANF	Can-Fite BioPharma Ltd.	269.00	268.00	26800.00%
IL:PPBT	Purple Biotech Ltd.	1.00	-0.30	-23.08%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 21, 2026

Biolight AI Stock Analysis